Name	Ishwar sharma	ID	MED111089111
Age & Gender	54Year(s)/MALE	Visit Date	5/16/2022 12:00:00 AM
Ref Doctor Name	MediWheel		

2 D ECHOCARDIOGRAPHIC STUDY

M mode measurement:

AORTA : 2.5cms

LEFT ATRIUM : 3.0cms

AVS :----

LEFT VENTRICLE (DIASTOLE) : 4.2cms

(SYSTOLE) : 2.8cms

VENTRICULAR SEPTUM (DIASTOLE) : 0.9cms

(SYSTOLE) : 1.3cms

POSTERIOR WALL (DIASTOLE) : 0.9cms

(SYSTOLE) : 1.2cms

EDV: 79ml

ESV : 30ml

FRACTIONAL SHORTENING : 33%

EJECTION FRACTION : 62%

EPSS :---

RVID : 1.3cms

DOPPLER MEASUREMENTS:

MITRAL VALVE : E' 0.50 m/s A' 0.84 m/s NO MR

AORTIC VALVE : 0.78 m/s NO AR

TRICUSPID VALVE : E' 1.88 m/s A' - m/s NO TR

PULMONARY VALVE : 0.78 m/s NO PR

Name	Ishwar sharma	ID	MED111089111
Age & Gender	54Year(s)/MALE	Visit Date	5/16/2022 12:00:00 AM
Ref Doctor Name	MediWheel	-	

2D ECHOCARDIOGRAPHY FINDINGS:

Left ventricle : Normal size, Normal systolic function.

No regional wall motion abnormalities.

Left Atrium : Normal.

Right Ventricle : Normal.

Right Atrium : Normal.

Mitral valve : Normal, No mitral valve prolapsed.

Aortic valve : Normal, Trileaflet.

Tricuspid valve : Normal.

Pulmonary valve : Normal.

IAS : Intact.

IVS : Intact.

Pericardium : No pericardial effusion.

IMPRESSION:

- > LV DIASTOLIC DYSFUNCTION
- > NORMAL SIZED CARDIAC CHAMBERS.
- > NORMAL LV SYSTOLIC FUNCTION. EF:62 %.
- > NO REGIONAL WALL MOTION ABNORMALITIES.
- > NORMAL VALVES.
- > NO CLOTS / PERICARDIAL EFFUSION / VEGETATION.

DR. K.S. SUBRAMANI. MBBS, MD, DM (CARDIOLOGY) FESC SENIOR CONSULTANT INTERVENTIONAL CARDIOLOGIST Kss/da

Name	Ishwar sharma	ID	MED111089111
Age & Gender	54Year(s)/MALE	Visit Date	5/16/2022 12:00:00 AM
Ref Doctor Name	MediWheel	•	•

- Note:

 * Report to be interpreted by qualified medical professional.

 * To be correlated with other clinical findings.

 * Parameters may be subjected to inter and intra observer variations.

CLUMAX DIAGNOSTICS

--- A MEDALL COMPANY ---

Date 16-May-2022 7:26 AM





Customer Name: MR.ISHWAR SHARMA

Ref Dr Name

: MediWheel

:MED111089111

Email Id

Corp Name

Customer Id

:MediWheel

Address

Pluse-8H BREAK FAST **EOMPLEMENTARY**

Package Name: Mediwheel Full Body Health Checkup Male Above 40

115-00 g Signature Seq Time **Accession No** S.No Modality Study BLOOD UREA NITROGEN LAB (BUN) CREATININE LAB 2 GLUCOSE - FASTING LAB 3 GLUCOSE - POSTPRANDIAL (2 LAB HRS) GLYCOSYLATED LAB HAEMOGLOBIN (HbA1c) URIC ACID LAB 6 LIPID PROFILE LAB 7 LIVER FUNCTION TEST (LFT) LAB 8 TOTAL PROSTATE SPECIFIC 9 LAB ANTIGEN - PSA THYROID PROFILE/ TFT(T3, LAB 10 T4, TSH) URINE GLUCOSE - FASTING LAB 11 URINE GLUCOSE -ROOL LAB 12 Robert POSTPRANDIAL (2 Hrs) COMPLETE BLOOD COUNT LAB 13 WITH ESR STOOL ANALYSIS - ROUTINE LAB 14 URINE ROUTINE LAB 15 BUN/CREATININE RATIO LAB 16 BLOOD GROUP & RH TYPE LAB 17

Name	Ishwar sharma	ID	MED111089111
Age & Gender	54Year(s)/MALE	Visit Date	5/16/2022 12:00:00 AM
Ref Doctor Name	MediWheel	-	

ABDOMINO-PELVIC ULTRASONOGRAPHY

LIVER is normal in shape, size and has uniform echopattern. No evidence of focal lesion or intrahepatic biliary ductal dilatation. Hepatic and portal vein radicals are normal.

GALL BLADDER shows normal shape and has clear contents. Gall bladder wall is of normal thickness. CBD is of normal calibre.

PANCREAS has normal shape, size and uniform echopattern. No evidence of ductal dilatation or calcification.

SPLEEN shows normal shape, size and echopattern. Spleen measures 9.4cms in long axis and 4.2cms in short axis.

No demonstrable Para -aortic lymphadenopathy.

KIDNEYS move well with respiration and have normal shape, size and echopattern. Cortico- medullary differentiations are well madeout. No evidence of calculus or hydronephrosis. A simple cortical cyst measuring about 1.3 x 1.2cms is noted in the upper pole of the right kidney.

The kidney measures as follows:

-	Bipolar length (cms)	Parenchymal thickness (cms)
Right Kidney	9.5	1.2
Left Kidney	9.7	1.3

URINARY BLADDER shows mildly (5-6mm) thickened walls. It has clear contents. No evidence of diverticula.

Prevoid: 180cc Postvoid: 10cc

PROSTATE is mildly enlarged in size. It measures 4.7 x 3.7 x 3.9cms (Vol:35cc).

No evidence of ascites / pleural effusion.

IMPRESSION:

- > MILD PROSTATOMEGALY.
- > CHANGES OF MILD CYSTITIS.

DR. H.K. ANAND CONSULTANT RADIOLOGISTS DR. MEERA S

Name	Ishwar sharma	ID	MED111089111
Age & Gender	54Year(s)/MALE	Visit Date	5/16/2022 12:00:00 AM
Ref Doctor Name	MediWheel	-	

Name	Ishwar sharma	Customer ID	MED111089111
Age & Gender	54Y/M	Visit Date	May 16 2022 7:26AM
Ref Doctor	MediWheel		

X - RAY CHEST PA VIEW

Bilateral lung fields appear normal.

Cardiac size is within normal limits.

Bilateral hilar regions appear normal.

Bilateral domes of diaphragm and costophrenic angles are normal.

Visualised bones and soft tissues appear normal.

IMPRESSION:

No significant abnormality detected.

DR. H.K. ANAND DR. SHWETHA S DR. CHARUL
CONSULTANT RADIOLOGISTS

DR. APARNA

 PID No.
 : MED111089111
 Register On
 : 16/05/2022 7:28 AM

 SID No.
 : 422042352
 Collection On
 : 16/05/2022 8:04 AM

 Age / Sex
 : 54 Year(s) / Male
 Report On
 : 16/05/2022 2:14 PM

 Type
 : OP
 Printed On
 : 19/05/2022 12:58 PM

Ref. Dr : MediWheel

<u>Investigation</u>	Observed Value	<u>Unit</u>	<u>Biological</u> <u>Reference Interval</u>
HAEMATOLOGY			
Complete Blood Count With - ESR			
Haemoglobin (EDTA Blood'Spectrophotometry)	13.9	g/dL	13.5 - 18.0
Packed Cell Volume(PCV)/Haematocrit (EDTA Blood)	43.9	%	42 - 52
RBC Count (EDTA Blood)	5.00	mill/cu.mm	4.7 - 6.0
Mean Corpuscular Volume(MCV) (EDTA Blood)	87.7	fL	78 - 100
Mean Corpuscular Haemoglobin(MCH) (EDTA Blood)	27.8	pg	27 - 32
Mean Corpuscular Haemoglobin concentration(MCHC) (EDTA Blood)	31.8	g/dL	32 - 36
RDW-CV (EDTA Blood)	13.2	%	11.5 - 16.0
RDW-SD (EDTA Blood)	40.52	fL	39 - 46
Total Leukocyte Count (TC) (EDTA Blood)	5900	cells/cu.mm	4000 - 11000
Neutrophils (EDTA Blood)	52.6	%	40 - 75
Lymphocytes (EDTA Blood)	35.4	%	20 - 45
Eosinophils (EDTA Blood)	3.5	%	01 - 06



VERIFIED BY



 PID No.
 : MED111089111
 Register On
 : 16/05/2022 7:28 AM

 SID No.
 : 422042352
 Collection On
 : 16/05/2022 8:04 AM

 Age / Sex
 : 54 Year(s) / Male
 Report On
 : 16/05/2022 2:14 PM

 Type
 : OP
 Printed On
 : 19/05/2022 12:58 PM

Ref. Dr : MediWheel

Investigation	Observed <u>Value</u>	<u>Unit</u>	<u>Biological</u> <u>Reference Interval</u>
Monocytes (EDTA Blood)	7.5	%	01 - 10
Basophils (Blood)	1.0	%	00 - 02
INTERPRETATION: Tests done on Automated Five P	art cell counter. All a	abnormal results are	e reviewed and confirmed microscopically.
Absolute Neutrophil count (EDTA Blood)	3.10	10^3 / μ1	1.5 - 6.6
Absolute Lymphocyte Count (EDTA Blood)	2.09	10^3 / μ1	1.5 - 3.5
Absolute Eosinophil Count (AEC) (EDTA Blood)	0.21	10^3 / μ1	0.04 - 0.44
Absolute Monocyte Count (EDTA Blood)	0.44	10^3 / μ1	< 1.0
Absolute Basophil count (EDTA Blood)	0.06	10^3 / μ1	< 0.2
Platelet Count (EDTA Blood)	199	$10^3 / \mu l$	150 - 450
MPV (EDTA Blood)	8.6	fL	7.9 - 13.7
PCT (EDTA Blood/Automated Blood cell Counter)	0.17	%	0.18 - 0.28
ESR (Erythrocyte Sedimentation Rate) (Citrated Blood)	12	mm/hr	< 20



VERIFIED BY



 PID No.
 : MED111089111
 Register On
 : 16/05/2022 7:28 AM

 SID No.
 : 422042352
 Collection On
 : 16/05/2022 8:04 AM

 Age / Sex
 : 54 Year(s) / Male
 Report On
 : 16/05/2022 2:14 PM

 Type
 : OP
 Printed On
 : 19/05/2022 12:58 PM

Ref. Dr : MediWheel

Investigation	Observed <u>Value</u>	<u>Unit</u>	<u>Biological</u> <u>Reference Interval</u>
BIOCHEMISTRY			
Liver Function Test			
Bilirubin(Total) (Serum/DCA with ATCS)	0.57	mg/dL	0.1 - 1.2
Bilirubin(Direct) (Serum/Diazotized Sulfanilic Acid)	0.21	mg/dL	0.0 - 0.3
Bilirubin(Indirect) (Serum/Derived)	0.36	mg/dL	0.1 - 1.0
SGOT/AST (Aspartate Aminotransferase) (Serum/Modified IFCC)	20.26	U/L	5 - 40
SGPT/ALT (Alanine Aminotransferase) (Serum/Modified IFCC)	12.52	U/L	5 - 41
GGT(Gamma Glutamyl Transpeptidase) (Serum/IFCC / Kinetic)	18.65	U/L	< 55
Alkaline Phosphatase (SAP) (Serum/Modified IFCC)	58.7	U/L	56 - 119
Total Protein (Serum/Biuret)	6.62	gm/dl	6.0 - 8.0
Albumin (Serum/Bromocresol green)	4.61	gm/dl	3.5 - 5.2
Globulin (Serum/Derived)	2.01	gm/dL	2.3 - 3.6
A : G RATIO (Serum/Derived)	2.29		1.1 - 2.2



 PID No.
 : MED111089111
 Register On
 : 16/05/2022 7:28 AM

 SID No.
 : 422042352
 Collection On
 : 16/05/2022 8:04 AM

 Age / Sex
 : 54 Year(s) / Male
 Report On
 : 16/05/2022 2:14 PM

 Type
 : OP
 Printed On
 : 19/05/2022 12:58 PM

Ref. Dr : MediWheel

Investigation	<u>Observed</u> <u>Value</u>	<u>Unit</u>	<u>Biological</u> <u>Reference Interval</u>
<u>Lipid Profile</u>			
Cholesterol Total (Serum/CHOD-PAP with ATCS)	138.03	mg/dL	Optimal: < 200 Borderline: 200 - 239 High Risk: >= 240
Triglycerides (Serum/GPO-PAP with ATCS)	96.11	mg/dL	Optimal: < 150 Borderline: 150 - 199 High: 200 - 499 Very High: >= 500

INTERPRETATION: The reference ranges are based on fasting condition. Triglyceride levels change drastically in response to food, increasing as much as 5 to 10 times the fasting levels, just a few hours after eating. Fasting triglyceride levels show considerable diurnal variation too. There is evidence recommending triglycerides estimation in non-fasting condition for evaluating the risk of heart disease and screening for metabolic syndrome, as non-fasting sample is more representative of the õusualö"circulating level of triglycerides during most part of the day.

part of the day.			
HDL Cholesterol (Serum/Immunoinhibition)	46.64	mg/dL	Optimal(Negative Risk Factor): >= 60 Borderline: 40 - 59 High Risk: < 40
LDL Cholesterol (Serum/Calculated)	72.2	mg/dL	Optimal: < 100 Above Optimal: 100 - 129 Borderline: 130 - 159 High: 160 - 189 Very High: >= 190
VLDL Cholesterol (Serum/Calculated)	19.2	mg/dL	< 30
Non HDL Cholesterol (Serum/Calculated)	91.4	mg/dL	Optimal: < 130 Above Optimal: 130 - 159 Borderline High: 160 - 189 High: 190 - 219 Very High: >= 220



 PID No.
 : MED111089111
 Register On
 : 16/05/2022 7:28 AM

 SID No.
 : 422042352
 Collection On
 : 16/05/2022 8:04 AM

 Age / Sex
 : 54 Year(s) / Male
 Report On
 : 16/05/2022 2:14 PM

 Type
 : OP
 Printed On
 : 19/05/2022 12:58 PM

Ref. Dr : MediWheel

<u>Investigation</u> <u>Observed</u> <u>Unit</u> <u>Biological</u> <u>Value</u> <u>Reference Interval</u>

INTERPRETATION: 1. Non-HDL Cholesterol is now proven to be a better cardiovascular risk marker than LDL Cholesterol. 2. It is the sum of all potentially atherogenic proteins including LDL, IDL, VLDL and chylomicrons and it is the "new bad cholesterol" and is a co-primary target for cholesterol lowering therapy.

Total Cholesterol/HDL Cholesterol Ratio 3 Optimal: < 3.3 (Serum/Calculated) Low Risk: 3.4 - 4.4

Average Risk: 4.5 - 7.1 Moderate Risk: 7.2 - 11.0 High Risk: > 11.0

Triglyceride/HDL Cholesterol Ratio 2.1 Optimal: < 2.5

(TG/HDL) Mild to moderate risk: 2.5 - 5.0

(Serum/Calculated) High Risk: > 5.0

LDL/HDL Cholesterol Ratio 1.5 Optimal: 0.5 - 3.0

(Serum/Calculated)
Borderline: 3.1 - 6.0
High Risk: > 6.0



 PID No.
 : MED111089111
 Register On
 : 16/05/2022 7:28 AM

 SID No.
 : 422042352
 Collection On
 : 16/05/2022 8:04 AM

 Age / Sex
 : 54 Year(s) / Male
 Report On
 : 16/05/2022 2:14 PM

 Type
 : OP
 Printed On
 : 19/05/2022 12:58 PM

Ref. Dr : MediWheel

Investigation	<u>Observed</u> <u>Value</u>	<u>Unit</u>	<u>Biological</u> <u>Reference Interval</u>
Glycosylated Haemoglobin (HbA1c)			
HbA1C (Whole Blood/HPLC)	7.6	%	Normal: 4.5 - 5.6 Prediabetes: 5.7 - 6.4 Diabetic: >= 6.5

INTERPRETATION: If Diabetes - Good control: 6.1 - 7.0 %, Fair control: 7.1 - 8.0 %, Poor control >= 8.1 %

Estimated Average Glucose 171.42 mg/dL

(Whole Blood)

INTERPRETATION: Comments

HbA1c provides an index of Average Blood Glucose levels over the past 8 - 12 weeks and is a much better indicator of long term glycemic control as compared to blood and urinary glucose determinations.

Conditions that prolong RBC life span like Iron deficiency anemia, Vitamin B12 & Folate deficiency,

hypertriglyceridemia, hyperbilirubinemia, Drugs, Alcohol, Lead Poisoning, Asplenia can give falsely elevated HbAlC values.

Conditions that shorten RBC survival like acute or chronic blood loss, hemolytic anemia, Hemoglobinopathies, Splenomegaly, Vitamin E ingestion, Pregnancy, End stage Renal disease can cause falsely low HbAlc.



 PID No.
 : MED111089111
 Register On
 : 16/05/2022 7:28 AM

 SID No.
 : 422042352
 Collection On
 : 16/05/2022 8:04 AM

 Age / Sex
 : 54 Year(s) / Male
 Report On
 : 16/05/2022 2:14 PM

 Type
 : OP
 Printed On
 : 19/05/2022 12:58 PM

Ref. Dr : MediWheel

InvestigationObservedUnitBiologicalValueReference Interval

IMMUNOASSAY

THYROID PROFILE / TFT

T3 (Triiodothyronine) - Total 0.909 ng/ml 0.4 - 1.81

(Serum/ECLIA)

INTERPRETATION:

Comment:

Total T3 variation can be seen in other condition like pregnancy, drugs, nephrosis etc. In such cases, Free T3 is recommended as it is Metabolically active.

T4 (Tyroxine) - Total 9.27 μ g/dl 4.2 - 12.0

(Serum/ECLIA)

INTERPRETATION:

Comment:

Total T4 variation can be seen in other condition like pregnancy, drugs, nephrosis etc. In such cases, Free T4 is recommended as it is Metabolically active.

TSH (Thyroid Stimulating Hormone) 1.61 µIU/mL 0.35 - 5.50

(Serum/ECLIA)

INTERPRETATION:

Reference range for cord blood - upto 20

1 st trimester: 0.1-2.5 2 nd trimester 0.2-3.0 3 rd trimester : 0.3-3.0

(Indian Thyroid Society Guidelines)

Comment:

- 1.TSH reference range during pregnancy depends on Iodine intake, TPO status, Serum HCG concentration, race, Ethnicity and BMI.
- 2.TSH Levels are subject to circadian variation, reaching peak levels between 2-4am and at a minimum between 6-10PM. The variation can be of the order of 50%, hence time of the day has influence on the measured serum TSH concentrations.
- 3. Values & amplt 0.03 µIU/mL need to be clinically correlated due to presence of rare TSH variant in some individuals.



VERIFIED BY



 PID No.
 : MED111089111
 Register On
 : 16/05/2022 7:28 AM

 SID No.
 : 422042352
 Collection On
 : 16/05/2022 8:04 AM

 Age / Sex
 : 54 Year(s) / Male
 Report On
 : 16/05/2022 2:14 PM

 Type
 : OP
 Printed On
 : 19/05/2022 12:58 PM

Ref. Dr : MediWheel

InvestigationObservedUnitBiologicalValueReference Interval

CLINICAL PATHOLOGY

PHYSICAL EXAMINATION (URINE COMPLETE)

Colour Pale Yellow Yellow to Amber

(Urine)

Appearance Clear Clear

(Urine)

Volume(CLU) 15

(Urine)

CHEMICAL EXAMINATION (URINE

<u>COMPLETE</u>)

pH 6.0 4.5 - 8.0

(Urine)

Specific Gravity 1.010 1.002 - 1.035

(Urine)

Ketone Negative Negative

(Urine)

Urobilinogen Normal Normal

(Urine)

(Urine)

Blood Negative Negative

Nitrite Negative

(Urine)

Bilirubin Negative Negative

(Urine)

Protein Negative Negative

(Urine)



VERIFIED BY



Negative

 PID No.
 : MED111089111
 Register On
 : 16/05/2022 7:28 AM

 SID No.
 : 422042352
 Collection On
 : 16/05/2022 8:04 AM

 Age / Sex
 : 54 Year(s) / Male
 Report On
 : 16/05/2022 2:14 PM

 Type
 : OP
 Printed On
 : 19/05/2022 12:58 PM

Ref. Dr : MediWheel

<u>Investigation</u> <u>Observed</u> <u>Unit</u> <u>Biological</u> <u>Value</u> <u>Reference Interval</u>

Glucose Negative Negative

(Urine/GOD - POD)

Leukocytes(CP) Negative

(Urine)

MICROSCOPIC EXAMINATION (URINE COMPLETE)

Pus Cells 0-1 /hpf NIL

(Urine)

Epithelial Cells 1-2 /hpf NIL

(Urine)

RBCs Nil /hpf NIL

(Urine)

Others

(Urine)

INTERPRETATION: Note: Done with Automated Urine Analyser & Automated urine sedimentation analyser. All abnormal reports are reviewed and confirmed microscopically.

Casts Nil /hpf NIL

(Urine)

Crystals Nil /hpf NIL

(Urine)



VERIFIED BY



 PID No.
 : MED111089111
 Register On
 : 16/05/2022 7:28 AM

 SID No.
 : 422042352
 Collection On
 : 16/05/2022 8:04 AM

 Age / Sex
 : 54 Year(s) / Male
 Report On
 : 16/05/2022 2:14 PM

 Type
 : OP
 Printed On
 : 19/05/2022 12:58 PM

Ref. Dr : MediWheel

<u>Investigation</u>	<u>Observed</u> <u>Uni</u>	<u>t</u> <u>Biological</u>
	Value	Reference Interval

PHYSICAL EXAMINATION(STOOL COMPLETE)

Mucus Absent Absent

(Stool)

Consistency Semi Solid Semi Solid to Solid

(Stool)

Colour Brownish Brown

(Stool)

Blood Absent Absent

(Stool)

<u>MICROSCOPIC EXAMINATION(STOOL</u> <u>COMPLETE)</u>

Ova NIL NIL

(Stool)

Cysts NIL NIL

(Stool)

Trophozoites NIL NIL

(Stool)

RBCs NIL /hpf Nil

(Stool)

Pus Cells 1-3 /hpf NIL

(Stool)

Others

(Stool)

<u>CHEMICAL EXAMINATION(STOOL</u> <u>ROUTINE)</u>



VERIFIED BY



 PID No.
 : MED111089111
 Register On
 : 16/05/2022 7:28 AM

 SID No.
 : 422042352
 Collection On
 : 16/05/2022 8:04 AM

 Age / Sex
 : 54 Year(s) / Male
 Report On
 : 16/05/2022 2:14 PM

 Type
 : OP
 Printed On
 : 19/05/2022 12:58 PM

Ref. Dr : MediWheel

<u>Investigation</u> <u>Observed</u> <u>Unit</u> <u>Biological</u> <u>Value</u> <u>Reference Interval</u>

Reaction Alkaline Alkaline

(Stool)

Reducing Substances Negative Negative

(Stool/Benedict's)



VERIFIED BY



 PID No.
 : MED111089111
 Register On
 : 16/05/2022 7:28 AM

 SID No.
 : 422042352
 Collection On
 : 16/05/2022 8:04 AM

 Age / Sex
 : 54 Year(s) / Male
 Report On
 : 16/05/2022 2:14 PM

 Type
 : OP
 Printed On
 : 19/05/2022 12:58 PM

Ref. Dr : MediWheel

InvestigationObservedUnitBiologicalValueReference Interval

IMMUNOHAEMATOLOGY

BLOOD GROUPING AND Rh TYPING 'B' 'Positive'

(EDTA Blood/Agglutination)



VERIFIED BY



 PID No.
 : MED111089111
 Register On
 : 16/05/2022 7:28 AM

 SID No.
 : 422042352
 Collection On
 : 16/05/2022 8:04 AM

 Age / Sex
 : 54 Year(s) / Male
 Report On
 : 16/05/2022 2:14 PM

 Type
 : OP
 Printed On
 : 19/05/2022 12:58 PM

Ref. Dr : MediWheel

Investigation	Observed Value	<u>Unit</u>	<u>Biological</u> <u>Reference Interval</u>
BIOCHEMISTRY			
BUN / Creatinine Ratio	6.9		6.0 - 22.0
Glucose Fasting (FBS) (Plasma - F/GOD-PAP)	149.11	mg/dL	Normal: < 100 Pre Diabetic: 100 - 125 Diabetic: >= 126

INTERPRETATION: Factors such as type, quantity and time of food intake, Physical activity, Psychological stress, and drugs can influence blood glucose level.

Glucose, Fasting (Urine)	Negative		Negative
(Urine - F/GOD - POD)			
Glucose Postprandial (PPBS)	169.00	mg/dL	70 - 140

(Plasma - PP/GOD-PAP)

INTERPRETATION:

Factors such as type, quantity and time of food intake, Physical activity, Psychological stress, and drugs can influence blood glucose level. Fasting blood glucose level may be higher than Postprandial glucose, because of physiological surge in Postprandial Insulin secretion, Insulin resistance, Exercise or Stress, Dawn Phenomenon, Somogyi Phenomenon, Anti- diabetic medication during treatment for Diabetes.

Urine Glucose(PP-2 hours) (Urine - PP)	Negative		Negative
Blood Urea Nitrogen (BUN) (Serum/Urease UV / derived)	7.2	mg/dL	7.0 - 21
Creatinine (Serum/Modified Jaffe)	1.03	mg/dL	0.9 - 1.3

INTERPRETATION: Elevated Creatinine values are encountered in increased muscle mass, severe dehydration, Pre-eclampsia, increased ingestion of cooked meat, consuming Protein/ Creatine supplements, Diabetic Ketoacidosis, prolonged fasting, renal dysfunction and drugs such as cefoxitin ,cefazolin, ACE inhibitors ,angiotensin II receptor antagonists,N-acetylcyteine , chemotherapeutic agent such as flucytosine etc.

Uric Acid 5.11 mg/dL 3.5 - 7.2 (Serum/Enzymatic)



 PID No.
 : MED111089111
 Register On
 : 16/05/2022 7:28 AM

 SID No.
 : 422042352
 Collection On
 : 16/05/2022 8:04 AM

 Age / Sex
 : 54 Year(s) / Male
 Report On
 : 16/05/2022 2:14 PM

 Type
 : OP
 Printed On
 : 19/05/2022 12:58 PM

Ref. Dr : MediWheel

<u>Investigation</u>	<u>Observed</u>	<u>Unit</u>	<u>Biological</u>
•	<u>Value</u>		Reference Interval
TRABATINIO A CICLANA			

IMMUNOASSAY

Prostate specific antigen - Total(PSA) 1.24 ng/ml Normal: 0.0 - 4.0 (Serum/Manometric method) Inflammatory & Non Malignant

conditions of Prostate & genitourinary system: 4.01 - 10.0 Suspicious of Malignant disease of

Prostate: > 10.0

INTERPRETATION: Analytical sensitivity: 0.008 - 100 ng/mL

PSA is a tumor marker for screening of prostate cancer. Increased levels of PSA are associated with prostate cancer and benign conditions like bacterial infection, inflammation of prostate gland and benign hypertrophy of prostate/ benign prostatic hyperplasia (BPH).

Transient elevation of PSA levels are seen following digital rectal examination, rigorous physical activity like bicycle riding, ejaculation within 24 hours.

PSA levels tend to increase in all men as they age.

Clinical Utility of PSA:

ÉIn the early detection of Prostate cancer.

ÉAs an aid in discriminating between Prostate cancer and Benign Prostatic disease.

ÉTo detect cancer recurrence or disease progression.



VERIFIED BY



APPROVED BY

-- End of Report --